Table 1 Baseline patient characteristics and association between residual disease and clinicopathologic variables.
Total | Residual disease | p-value | ||
|---|---|---|---|---|
no | yes | |||
Number of patients | 558 | 313 | 245 | |
Age | 0.035 | |||
< 50 years | 355 (63.6) | 211 (67.4) | 144 (58.8) | |
≥ 50 years | 203 (36.4) | 102 (32.6) | 101 (41.2) | |
Tumor grade | 0.002 | |||
G1/2 | 452 (81.0) | 242 (77.3) | 210 (85.7) | |
G3 | 102 (18.3) | 71 (22.7) | 31 (12.7) | |
Unknown | 4 (0.7) | 0 (0.0) | 4 (1.6) | |
Estrogen Receptor | 0.007 | |||
Negative | 108 (19.4) | 73 (23.3) | 35 (14.3) | |
Positive | 450 (80.6) | 240 (76.7) | 210 (85.7) | |
Progesterone Receptor | 0.011 | |||
Negative | 187 (33.5) | 119 (38.0) | 68 (27.8) | |
Positive | 371 (66.5) | 194 (62.0) | 177 (72.2) | |
HER2 status | 0.393 | |||
Negative | 437 (78.3) | 241 (77.0) | 196 (80.0) | |
Positive | 121 (21.7) | 72 (23.0) | 49 (20.0) | |
Biological Subtype | 0.039 | |||
HR+/HER2− | 379 (67.9) | 199 (63.6) | 180 (73.5) | |
HR+/HER2+ | 72 (12.9) | 41 (13.1) | 31 (12.7) | |
HR−/HER2+ | 44 (7.9) | 30 (9.6) | 14 (5.7) | |
HR−/HER2− | 63 (11.3) | 43 (13.7) | 20 (8.2) | |
Initial T stage | 0.165 | |||
1 | 54 (9.7) | 32 (10.2) | 22 (9.0) | |
2 | 354 (63.4) | 208 (66.5) | 146 (59.6) | |
3 | 138 (24.7) | 66 (21.1) | 72 (29.4) | |
4 | 12 (2.2) | 7 (2.2) | 5 (2.0) | |
Initial N stage | < 0.001 | |||
0 | 92 (16.5) | 65 (20.7) | 27 (11.0) | |
1 | 415 (74.4) | 229 (73.2) | 186 (75.9) | |
2 | 51 (9.1) | 19 (6.1) | 32 (13.1) | |
Response to NAC | 0.891 | |||
Complete remission | 22 (3.9) | 14 (4.5) | 8 (3.3) | |
Partial remission | 406 (72.8) | 228 (72.8) | 178 (72.7) | |
Stable disease | 119 (21.3) | 65 (20.8) | 54 (22.0) | |
Progressive disease | 11 (2.0) | 6 (1.9) | 5 (2.0) | |
Surgery type | 0.079 | |||
Breast conserving surgery | 258 (46.2) | 155 (49.5) | 103 (42.0) | |
Mastectomy | 300 (53.8) | 158 (50.5) | 142 (58.0) | |
Number of positive SLNs | < 0.001 | |||
1 | 284 (50.9) | 185 (59.1) | 99 (40.4)) | |
2 | 203 (36.4) | 106 (33.9) | 97 (39.6) | |
3 | 71 (12.7) | 22 (7.0) | 49 (20.0) | |
Pathologic T stage | 0.001 | |||
0 | 29 (5.2) | 18 (5.8) | 11 (4.5) | |
1 | 235 (42.1) | 150 (47.9) | 85 (34.7) | |
2 | 238 (42.7) | 124 (39.6) | 114 (46.5) | |
3 | 56 (10.0) | 21 (6.7) | 35 (14.3) | |
Pathologic N stage | < 0.001 | |||
1 | 419 (75.1) | 309 (98.7) | 110 (44.9) | |
2 | 139 (24.9) | 4 (1.3) | 135 (55.1) | |
